Fortress Biotech
2 Gansevoort Street
9th Floor
New York
New York
10014
United States
Tel: 781-652-4500
Website: http://www.fortressbiotech.com/
Email: info@fortressbiotech.com
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies, also known as Fortress Companies. Additionally, Fortress recently acquired a controlling interest in National Holdings Corporation (NASDAQ: NHLD), a diversified independent brokerage company (together with its subsidiaries, “NHLD”). In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies achieve their goals. Fortress and the Fortress Companies may seek licensings, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs.
LEADERSHIP:
CEO: Lindsay A. Rosenwald
CFO: Robyn Hunter
224 articles about Fortress Biotech
-
Coronado Biosciences Announces IND Submission for CNDO-109 for the Treatment of Relapsed Acute Myeloid Leukemia
2/14/2012
-
Coronado Biosciences to Present at the Leerink Swann and Company 2012 Global Healthcare Conference
2/13/2012
-
Coronado Biosciences to Present at 30th Annual JP Morgan Healthcare Conference
1/12/2012
-
Coronado Biosciences to Present at the Biotech Showcase 2012 Conference
1/6/2012
-
Coronado Biosciences President and CEO to Ring The NASDAQ Stock Market Closing Bell
12/20/2011
-
Coronado Biosciences Appoints Karin Hehenberger, M.D., Ph.D. as Senior Vice President of Scientific Affairs
12/20/2011
-
Coronado Biosciences Approved for Listing on NASDAQ
12/16/2011
-
Coronado Biosciences is Granted First Patent for CNDO-10
12/14/2011
-
Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML Presented at the American Society of Hematology
12/13/2011
-
Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
12/8/2011
-
Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
12/7/2011
-
Coronado Biosciences Commences Public Trading on the OTC Bulletin Board
11/18/2011
-
Coronado Biosciences Reports Third Quarter 2011 Financial Results
11/15/2011
-
Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
10/3/2011
-
Coronado Biosciences to Present at the Rodman & Renshaw Annual Global Investment Conference
9/6/2011
-
Coronado Biosciences Plans Two Drug Trials, Wall Street Debut, and Boston Move; Uses a Parasitic Worm to Fight Crohn’s Disease
7/26/2011
-
Coronado Biosciences Files to Become a Public Reporting Company
7/18/2011
-
Coronado Biosciences Closes $25.8 Million in Series C Financing
7/7/2011
-
Coronado Biosciences Announces Completion of Financings, Management Changes and Development Update; Appoints New CEO
11/4/2010
-
Coronado Biosciences Nabs $7 Million
5/11/2010